ATE365801T1 - Modulierung durch il-tif/interleukin-21 - Google Patents

Modulierung durch il-tif/interleukin-21

Info

Publication number
ATE365801T1
ATE365801T1 AT01952260T AT01952260T ATE365801T1 AT E365801 T1 ATE365801 T1 AT E365801T1 AT 01952260 T AT01952260 T AT 01952260T AT 01952260 T AT01952260 T AT 01952260T AT E365801 T1 ATE365801 T1 AT E365801T1
Authority
AT
Austria
Prior art keywords
molecules
nucleic acid
proteins
interleukin
tif
Prior art date
Application number
AT01952260T
Other languages
English (en)
Inventor
Laure Dumoutier
Jean-Christophe Renauld
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Application granted granted Critical
Publication of ATE365801T1 publication Critical patent/ATE365801T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • AIDS & HIV (AREA)
AT01952260T 2000-07-27 2001-06-27 Modulierung durch il-tif/interleukin-21 ATE365801T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US62661700A 2000-07-27 2000-07-27

Publications (1)

Publication Number Publication Date
ATE365801T1 true ATE365801T1 (de) 2007-07-15

Family

ID=24511131

Family Applications (2)

Application Number Title Priority Date Filing Date
AT01952260T ATE365801T1 (de) 2000-07-27 2001-06-27 Modulierung durch il-tif/interleukin-21
AT07002409T ATE478148T1 (de) 2000-07-27 2001-06-27 Verwendung von il-10 rezeptor beta antagonistische antikörper zur hemmung einer il- tif/il-21 induktion von akutphasen-proteine

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT07002409T ATE478148T1 (de) 2000-07-27 2001-06-27 Verwendung von il-10 rezeptor beta antagonistische antikörper zur hemmung einer il- tif/il-21 induktion von akutphasen-proteine

Country Status (9)

Country Link
EP (2) EP1806404B1 (de)
JP (1) JP4113773B2 (de)
CN (3) CN100448994C (de)
AT (2) ATE365801T1 (de)
AU (1) AU7303301A (de)
CA (1) CA2416820A1 (de)
DE (2) DE60142861D1 (de)
ES (1) ES2349312T3 (de)
WO (1) WO2002010393A2 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7307161B1 (en) 1999-04-28 2007-12-11 Genetics Institute, Llc Human Gil-19/AE289 polynucleotides
US6939545B2 (en) 1999-04-28 2005-09-06 Genetics Institute, Llc Composition and method for treating inflammatory disorders
US20030170823A1 (en) 1999-12-23 2003-09-11 Presnell Scott R. Novel cytokine ZCYTO18
US20030023033A1 (en) * 2001-07-26 2003-01-30 Laure Dumoutier Novel class II cytokine receptors and uses thereof
US20030012788A1 (en) 2000-07-27 2003-01-16 Jean-Christophe Renauld Method for influencing kinase pathways with IL-22
WO2002033083A2 (en) * 2000-10-13 2002-04-25 Eli Lilly And Company Methods of using a human il-17-related polypeptide to treat disease
US7638604B2 (en) 2001-02-23 2009-12-29 Genetics Institute, Llc Monoclonal antibodies against interleukin-22
US7265211B2 (en) 2002-03-22 2007-09-04 Zymogenetics, Inc. Anti-IL-TIF antibodies and methods of making
AU2003251633A1 (en) 2002-07-01 2004-01-19 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Il-21 as a regulator of immunoglobin production
WO2004024076A2 (en) * 2002-09-11 2004-03-25 Genentech, Inc. Novel compositions and methods for the treatment of immune related diseases
AU2003273758A1 (en) * 2002-10-11 2004-05-04 Novo Nordisk A/S Treatment of allergic conditions by use of il 21
EP1782823A3 (de) * 2002-10-11 2007-05-16 Novo Nordisk A/S IL-21 Peptiden und Nukleinsäuren
RU2006101702A (ru) * 2003-06-23 2006-09-10 Дженетикс Инститьют, Ллс (Us) Антитела против интерлейкина-22 и их применения
WO2007126439A2 (en) 2005-12-02 2007-11-08 Genentech, Inc. Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to il-22 and il-22r
TW200744634A (en) 2006-02-21 2007-12-16 Wyeth Corp Methods of using antibodies against human IL-22
TWI417301B (zh) 2006-02-21 2013-12-01 Wyeth Corp 對抗人類介白素-２２（ｉｌ-２２）之抗體及其用途
IT1404858B1 (it) 2011-02-21 2013-12-09 Milano Politecnico Supporto anti-sismico.
US20240026014A1 (en) * 2020-08-05 2024-01-25 Synthekine, Inc. Compositions and methods related to receptor pairings

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843697A (en) 1996-07-17 1998-12-01 University Of Medicine And Dentistry Of New Jersey Cells expressing IL-10 receptor and the CRFB4 gene product, an IL-10 receptor accessory protein
DE19848683B4 (de) 1998-10-22 2004-05-06 Basf Ag Verbundschichtplatte
CN1238367C (zh) * 1998-10-26 2006-01-25 路德维格癌症研究院 分离的编码t细胞诱导因子(tif)的核酸分子,其编码蛋白及其应用
ES2295026T3 (es) * 1999-04-28 2008-04-16 Genetics Institute, Llc Proteinas gil-19/ae289 humanas y polinucleotidos que codifican las mismas.
AU5047600A (en) * 1999-05-27 2000-12-18 Schering Corporation Mammalian interleukin-10 homologs: il-d110 and il-d210
EP1234035B1 (de) * 1999-12-03 2010-02-24 ZymoGenetics, Inc. Menschliches zytokinrezeptor

Also Published As

Publication number Publication date
ATE478148T1 (de) 2010-09-15
CN100497628C (zh) 2009-06-10
AU7303301A (en) 2002-02-13
EP1305419A2 (de) 2003-05-02
DE60142861D1 (de) 2010-09-30
WO2002010393A3 (en) 2003-01-30
CA2416820A1 (en) 2002-02-07
EP1806404B1 (de) 2010-08-18
EP1305419B1 (de) 2007-06-27
ES2349312T3 (es) 2010-12-29
JP2004504842A (ja) 2004-02-19
EP1806404A1 (de) 2007-07-11
CN1796558A (zh) 2006-07-05
CN1443241A (zh) 2003-09-17
WO2002010393A2 (en) 2002-02-07
JP4113773B2 (ja) 2008-07-09
CN101423551A (zh) 2009-05-06
CN100448994C (zh) 2009-01-07
DE60129137D1 (de) 2007-08-09

Similar Documents

Publication Publication Date Title
DE60129137D1 (de) Modulierung durch il-tif/interleukin-21
ATE469911T1 (de) Isolierte nukleinsäuremoleküle die t-zellen induzierbare faktoren kodieren (tif), kodierte proteine und ihre anwendung
BRPI0512396A (pt) polipeptìdeos biossintéticos utilizando aminoácidos codificados não naturalmente
ATE500323T1 (de) Subtilisin-variante
CY1112198T1 (el) Αναλογα κομπστατινης με βελτιωμενη δραστικοτητα
EP1019365A4 (de) Zubereitungen zur abgabe von negativ geladenen molekülen
ATE536369T1 (de) Im wesentlichen ph-wert-unabhängigerweise an serumproteine bindende aminosäuresequenzen, verbindungen, die diese enthalten, und deren verwendung
DK1458760T3 (da) Indfangede bindingsproteiner som biosensorer
NO20043259L (no) Bindingsproteiner som biosensorer
DK1084146T3 (da) Hybridprotein til inhibering af degranuleringen af mastocyter og anvendelse deraf
DK1015586T3 (da) TIE-receptortyrosinkinaseligandhomologer
ATE451390T1 (de) Polypeptide zur bindung an das b-lymphozyten- stimulatorische protein (blys)
NO20082783L (no) Induserbare ekspresjonssystemer
DE69942861D1 (de) Ldcam genannte moleküle
WO2005017205A3 (en) Nucleic acid mapping using linear analysis
DE50112802D1 (de) Peptide, deren herstellung und verwendung zur bindung von immunglobulinen
DK1536778T3 (da) Proteiner, der binder til cross-beta-strukturholdigt amyloid og fremgangsmåder til modulation af cross-beta-strukturen, dens dannelse og dens associerede toksicitet
BR0312521A (pt) Métodos para a separação e a purificação de fibrinogênio e de pelo menos uma outra proteìna e para a co-purificação de fibrinogênio e de fator xiii, uso de cromatografia de afinidade com ìon de metal imobilizado, fibrinogênio, kit farmacêutico, e, formulações farmacêutica e de fibrinogênio liofilizado
GEAP202516650A (en) Stabilized pre-fusion hmpv fusion proteins
ATE403729T1 (de) Frostschutzproteine aus basidiomyceten
WO2003050283A3 (en) A structure for presenting desired peptide sequences
DE60141588D1 (de) Nukleinsäuresequenz und protein, das eine rolle bei der zellulären alterung spielt
EA200600042A1 (ru) Способы образования дисульфидных связей и гликозилирования белков и реагенты, применяемые в этих способах
DK1465927T3 (da) BAG3-antistoffer til anvendelse til forskning, diagnostik og behandling af sygdomme, der omfatter celledød
EA200401032A1 (ru) Антиинфарктные молекулы

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties
REN Ceased due to non-payment of the annual fee
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties